We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cannabis Operator CRON Rises 46% in a Year: Time to Buy, Sell or Hold?
Read MoreHide Full Article
Key Takeaways
Cronos Group shares surged 46% in a year, driven by strong fundamentals and macro optimism.
CRON's international revenues rose sharply, led by Israel and Europe, boosting margins to 43%.
Cronos faces rising competition and execution risks despite expansion and acquisition plans.
Shares of Cronos Group (CRON - Free Report) have staged a strong recovery over the past year. The Canada-based cannabis operator’s shares have risen 46% in the said time frame, significantly outperforming the industry, as shown in the chart below.
Image Source: Zacks Investment Research
The rally can be attributed to improving business fundamentals and favorable macro developments. Cronos reported strong top-line growth in recent quarters, driven largely by robust international performance, particularly in Israel. At the same time, expanding gross margins and ongoing cost discipline have reflected better execution and operating leverage, reinforcing investor confidence in the company’s trajectory. Optimism around potential federal marijuana reform in the United States has also contributed to the positive sentiment.
This surge has investors questioning whether to buy, hold, or sell the stock. Let’s examine the company’s fundamentals to better assess the appropriate course of action.
CRON’s International Business Drives Top-Line Growth
Cronos Group’s international business emerged as a key growth engine in 2025, driving strong top-line expansion and improving overall profitability. The company delivered a record year, with net revenues rising 25% year over year to $146.6 million, supported by continued momentum across its global markets.
International performance was particularly robust, led by Israel, where revenues grew 47% year over year to $41.8 million. CRON’s Peace Naturals brand maintained its leadership position in the country, benefiting from strong demand, consistent product quality and effective commercial execution. Excluding Israel, sales in other international markets rose 112% year over year to $14.5 million, driven by growing demand across Europe, where the company’s products continued to gain traction, alongside the ongoing expansion of its global distribution footprint.
This expanding international footprint remains central to Cronos’ long-term strategy, offering higher average selling prices and more favorable margin structures than in the Canadian market. The shift toward international sales, combined with higher volumes, supported gross margin expansion, with the full-year adjusted gross margin reaching 43%, up from 26% in the prior year.
Overall, Cronos’ international momentum not only offset ongoing pricing pressures in Canada but also reinforced its ability to drive profitable growth through geographic diversification and disciplined execution.
Cronos is also expanding its international presence through strategic investments in Europe. In December, the company announced the acquisition of CanAdelaar, a leading participant in the Netherlands’ regulated cannabis program. The transaction is expected to be closed in the first half of 2026 and provide Cronos with direct exposure to one of Europe’s most structured and potentially scalable cannabis markets.
This move aligns with the company’s broader strategy of building a diversified global platform and leveraging its operational expertise in high-margin international markets, positioning it for incremental revenue growth and long-term value creation.
Stiff Competition From Other Cannabis Players
Cronos competes in an overcrowded market, facing pressure from peers like Curaleaf Holdings (CURLF - Free Report) and Tilray Brands (TLRY - Free Report) , which are also pursuing international expansion and cost optimization strategies. As CRON gains ground in international markets, competitive responses from Curaleaf and Tilray could intensify.
As Cronos strengthens its presence in global markets, competitive intensity is likely to increase, particularly as peers scale their international operations and seek to capture similar growth opportunities. With multiple players targeting the same markets, sustaining market share gains and pricing power could remain challenging.
Estimate Movements for CRON
Bottom-line estimates for 2026 have remained unchanged over the past 60 days, indicating stable earnings expectations in the near term.
Image Source: Zacks Investment Research
How to Play CRON Stock?
Cronos currently carries a Zacks Rank #3 (Hold), suggesting a wait-and-watch approach may be prudent for investors at current levels. While the company is benefiting from improving fundamentals, particularly in its international business, near-term upside could be balanced by execution risks and a highly competitive industry landscape.
Cronos is actively evaluating strategic growth opportunities, including potential mergers and acquisitions, as highlighted in its recent earnings call. The planned acquisition of CanAdelaar and management’s openness to further international expansion indicate that inorganic growth could play a meaningful role in shaping the company’s long-term trajectory. However, the timing, scale and integration of such deals remain key variables to monitor.
Given these factors, existing investors may consider holding their positions while closely tracking execution on international expansion, margin sustainability and progress on strategic initiatives. Prospective investors may prefer to wait for clearer visibility on earnings growth and the successful integration of upcoming acquisitions before taking fresh positions in the stock.
View the Zacks #1 Rank List
Image: Bigstock
Cannabis Operator CRON Rises 46% in a Year: Time to Buy, Sell or Hold?
Key Takeaways
Shares of Cronos Group (CRON - Free Report) have staged a strong recovery over the past year. The Canada-based cannabis operator’s shares have risen 46% in the said time frame, significantly outperforming the industry, as shown in the chart below.
Image Source: Zacks Investment Research
The rally can be attributed to improving business fundamentals and favorable macro developments. Cronos reported strong top-line growth in recent quarters, driven largely by robust international performance, particularly in Israel. At the same time, expanding gross margins and ongoing cost discipline have reflected better execution and operating leverage, reinforcing investor confidence in the company’s trajectory. Optimism around potential federal marijuana reform in the United States has also contributed to the positive sentiment.
This surge has investors questioning whether to buy, hold, or sell the stock. Let’s examine the company’s fundamentals to better assess the appropriate course of action.
CRON’s International Business Drives Top-Line Growth
Cronos Group’s international business emerged as a key growth engine in 2025, driving strong top-line expansion and improving overall profitability. The company delivered a record year, with net revenues rising 25% year over year to $146.6 million, supported by continued momentum across its global markets.
International performance was particularly robust, led by Israel, where revenues grew 47% year over year to $41.8 million. CRON’s Peace Naturals brand maintained its leadership position in the country, benefiting from strong demand, consistent product quality and effective commercial execution. Excluding Israel, sales in other international markets rose 112% year over year to $14.5 million, driven by growing demand across Europe, where the company’s products continued to gain traction, alongside the ongoing expansion of its global distribution footprint.
This expanding international footprint remains central to Cronos’ long-term strategy, offering higher average selling prices and more favorable margin structures than in the Canadian market. The shift toward international sales, combined with higher volumes, supported gross margin expansion, with the full-year adjusted gross margin reaching 43%, up from 26% in the prior year.
Overall, Cronos’ international momentum not only offset ongoing pricing pressures in Canada but also reinforced its ability to drive profitable growth through geographic diversification and disciplined execution.
Cronos is also expanding its international presence through strategic investments in Europe. In December, the company announced the acquisition of CanAdelaar, a leading participant in the Netherlands’ regulated cannabis program. The transaction is expected to be closed in the first half of 2026 and provide Cronos with direct exposure to one of Europe’s most structured and potentially scalable cannabis markets.
This move aligns with the company’s broader strategy of building a diversified global platform and leveraging its operational expertise in high-margin international markets, positioning it for incremental revenue growth and long-term value creation.
Stiff Competition From Other Cannabis Players
Cronos competes in an overcrowded market, facing pressure from peers like Curaleaf Holdings (CURLF - Free Report) and Tilray Brands (TLRY - Free Report) , which are also pursuing international expansion and cost optimization strategies. As CRON gains ground in international markets, competitive responses from Curaleaf and Tilray could intensify.
As Cronos strengthens its presence in global markets, competitive intensity is likely to increase, particularly as peers scale their international operations and seek to capture similar growth opportunities. With multiple players targeting the same markets, sustaining market share gains and pricing power could remain challenging.
Estimate Movements for CRON
Bottom-line estimates for 2026 have remained unchanged over the past 60 days, indicating stable earnings expectations in the near term.
Image Source: Zacks Investment Research
How to Play CRON Stock?
Cronos currently carries a Zacks Rank #3 (Hold), suggesting a wait-and-watch approach may be prudent for investors at current levels. While the company is benefiting from improving fundamentals, particularly in its international business, near-term upside could be balanced by execution risks and a highly competitive industry landscape.
Cronos is actively evaluating strategic growth opportunities, including potential mergers and acquisitions, as highlighted in its recent earnings call. The planned acquisition of CanAdelaar and management’s openness to further international expansion indicate that inorganic growth could play a meaningful role in shaping the company’s long-term trajectory. However, the timing, scale and integration of such deals remain key variables to monitor.
Given these factors, existing investors may consider holding their positions while closely tracking execution on international expansion, margin sustainability and progress on strategic initiatives. Prospective investors may prefer to wait for clearer visibility on earnings growth and the successful integration of upcoming acquisitions before taking fresh positions in the stock.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.